In the press
Wall Street Journal
Wall Street Journal
The following was taken from the Wall Street Journal. Check out the original piece here: https://www.wsj.com/articles/vc-daily-biotechs-test-new-company-building-model-11614261635
We are incredibly excited and humbled to be recognized in the Wall Street Journal for our innovative business model!
We thank everyone who has been supporting us from the beginning.
Related Press
New York biotech firm moving HQ to Cincinnati
New York biotech firm moving HQ to Cincinnati The following excerpt was taken from Cincyinno Business Journal — continue reading here. A New York-based biotech firm is moving its corporate headquarters to the University of Cincinnati’s 1819 Innovation Hub “A New York-based biotech firm is moving its corporate headquarters to the University of Cincinnati’s 1819
Orange Grove Bio and University of Chicago Form Strategic Partnership to Accelerate Biotech Innovation and Commercialization
Collaboration Aims to Bridge the Gap Between Academic Research and Commercial Development, Fostering a Thriving Biotech Ecosystem in Chicago CINCINNATI, Ohio, July 23, 2024 — Orange Grove Bio, a leading integrated biopharmaceutical company, and the University of Chicago’s Polsky Center for Entrepreneurship and Innovation today announced a strategic partnership to catalyze the successful commercialization of
Upcoming Webinar for Pre-Clinical Biotech Development Opportunities on April 16th at 1 PM EST.
Upcoming Webinar for Pre-Clinical Biotech Development Opportunities on April 16th at 1 PM EST. Please join us to hear from our CEO, Marc Appel.– continue reading here. Upcoming Webinar for Pre-Clinical Biotech Development Opportunities
Our first portfolio company, Asalyxa Bio, has launched
Our first portfolio company, Asalyxa Bio, has launched. The University of Michigan, our partner in the creation of this company, released a press release which can be read below. — Asalyxa Bio, a startup with neutrophil targeting drug-delivery technology invented at University of Michigan Asalyxa Bio, a startup with neutrophil targeting drug-delivery technology invented at
1819 Innovation Hub tenant inks key partnership with Korea VC firm
1819 Innovation Hub tenant inks key partnership with Korea VC firm The following excerpt was taken from TechOhio– continue reading here. A biotech firm that moved its headquarters from New York to Cincinnati in late 2021 has announced its first major collaboration A biotech firm that moved its headquarters from New York to Cincinnati in
Leading Korean VC partners with USA’s Orange Grove
Orange Grove Bio, a USA-based pre-clinical drug investment and development firm, and SV Investment, a South Korea-based venture capital and private equity firm, today announced the establishment of a new partnership through which the companies will collaborate on jointly sourcing and developing novel therapeutics in the USA and Korea. As priority partners, the companies will cultivate the US and Korean biotech landscape through technology licensing and company creation in their respective geographic areas.
Under terms of the partnership, SV Investment will leverage its relationships with biotech companies and academic institutions in Korea to identify licensing opportunities for promising early-stage research in the area of drug development. As part of the agreement, Marc Appel, chief executive of Orange Grove, will join SV Investment as a venture partner and will play a key role in evaluating the licensing opportunities that are identified at Korean biotech companies and universities. As appropriate, Orange Grove will work to license these technologies as a basis for life science company creation in the USA, with SV Investment serving as an early-stage investor in the companies.
Research Bridge Partners’ Seed Capital Investment in Asalyxa Bio
Research Bridge Partners’ Seed Capital Investment in Asalyxa Bio The following was taken from PR Newswire and you can read it here: https://www.prnewswire.com/news-releases/research-bridge-partners-seed-capital-investment-in-asalyxa-bio-advances-dr-lola-eniola-adefesos-immune-cell-targeted-therapeutic-platform-301242853.html “Research Bridge Partners – a 501 (c) (3) organization that bridges preeminent innovators at mid-continent research universities AUSTIN, Texas, March 9, 2021 /PRNewswire/ — Research Bridge Partners – a 501 (c) (3)
IpiNovyx Bio Awarded NIH Catalyze Award to Advance Novel Proteasome Therapeutic for Systemic Sclerosis-Associated Interstitial Lung Disease
Funding to Support Preclinical Development of First-in-Class Inhaled Therapy Targeting Lung Inflammation and Fibrosis Cincinnati, OH, May 11, 2026 — IpiNovyx Bio, a biotechnology company developing best-in-class proteasome modulating therapeutics, and launched by Orange Grove Bio, today announced it has been selected to receive support from the National Heart, Lung, and Blood Institute’s (NHLBI) Catalyze
Pre-clinical Biotech Development Opportunity Video
Pre-clinical Biotech Development Opportunity Video